The gut microbiome plays a crucial role in health and has been linked to various diseases. Our research focuses on understanding how the gut microbiome responds to commonly prescribed drugs, whether these responses cluster based on drug structure/classification, how responses differ among individuals, and the influence of the basal Antimicrobial Resistance (AMR) present in the microbiome on its response to drugs. Using the RapidAIM ex vivo assay, we have screened the effects of over 320 structurally diverse drugs on the microbiomes of six healthy adults. Each microbiome underwent deep sequencing, and their functional responses to drugs were monitored through over 1,800 metaproteomic experiments and targeted metabolomics. Our findings suggest that microbiome responses to drugs partially cluster based on drug structures and classes, that individual differences significantly affect these responses, and that baseline AMR levels in the microbiome greatly impact its functional redundancy and drug response.